Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis B

Conference Reports for NATAP

The Liver Meeting
AASLD 2025
Washington, D.C.
November 7-11, 2025


Safety, Tolerability, Immunogenicity, and Antiviral Efficacy of GS-2829 and GS-6779, a Novel, Arenaviral-Vectored, Therapeutic Hepatitis B Vaccine: Results From a Phase 1b Study in Virally Suppressed Patients With Chronic Hepatitis B

	AASLD 2025 Nov 7-11 Wash DC